Cardiome Pharma (CRME) Stock Price, News & Analysis

Company Overview

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $2.30 to $2.45
• 50-Day Range: N/A
• 52-Week Range: $1.29 to $4.84
• Volume: 90,444 shs
• Average Volume: 135,322 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CRME Stock Analysis - Frequently Asked Questions

How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) announced its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company had revenue of $6.54 million for the quarter, compared to the consensus estimate of $7.34 million.

What other stocks do shareholders of Cardiome Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiome Pharma investors own include Energy Transfer (ET), CBL & Associates Properties (CBL), Cornerstone Strategic Investment Fund (CLM), Cornerstone Total Return Fund (CRF), SandRidge Permian Trust (PER), SunCoke Energy Partners (SXCP) and Martin Midstream Partners (MMLP).

Company Calendar

• Last Earnings: 5/15/2018
• Today: 6/17/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CRME
• CIK: 1036141
• Web: www.cardiome.com
• Phone: 604-677-6905
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A